Watch the unveiling of the MiSeq i100 Series in this webinar. Discover how it will accelerate insights and discoveries with faster, simpler sequencing.
The excitement surrounding immuno-oncology is being driven by results seen in the clinic. New treatments can potentially be made more efficacious using NGS technology that would accelerate biomarker identification and bring down costs for research subject screening and safety monitoring. Among these technologies is RNA-Seq, a flexible sequencing assay that enables multiple applications with one assay from a single sample. In this webinar, we'll summarize the clinical relevance of RNA-Seq, when and how to use expression profiling economically, some common challenges and associated remedies.
Key learning objectives | |||||||||
|
|||||||||
![]() |
As researchers seek to understand how the transcriptome shapes biology, RNA-Seq is
becoming recognized as one of the most significant and powerful tools in modern science. With RNA-Seq, researchers can detect the fine architecture of the transcriptome, such as transcript isoforms, gene fusions, single nucleotide variants, and other features—without prior knowledge. In addition to RNA-Seq, methylation sequencing can provide insights into the regulation of RNA and the temporal and spatial expression of gene products. By combining both RNA and methylation sequencing, researchers who study complex disease, cancer, and other biological systems will have a more complete picture of the transcriptome and its underlying regulatory features.
In this live webinar, we discuss the RNA-Seq and Methyl-Seq workflows that can help researchers drive breakthroughs and understanding in the area of gene expression and gene regulation. Join our gene expression and methylation experts as they review how researchers are driving discovery and learn how our workflows can help your lab leverage the power of next-generation sequencing.
Discover a new era of sequencing with the NovaSeq Series. Join us for a live webinar event to see firsthand how we are redefining what is possible with high-throughput sequencing. Built from the ground up to fulfill your scientific visions, the NovaSeq Series gives you the flexibility and scalability to complete projects faster and more economically than ever before across a broad range of applications.
Webinar at a glance
The Webinar Series will feature HLA laboratory directors presenting case studies from samples prepared with TruSight HLA , sequenced with Illumina next-generation sequencing (NGS) MiSeq or MiniSeq systems, and analyzed using TruSight HLA Assign software.
Brugada Syndrome belongs to a family of rare inherited cardiac disorders that can lead to sudden cardiac death. Rare genetic variants in the SCN5A gene can be identified in ~20%* of cases with Brugada Syndrome, while the genetic basis in the others remains unresolved.
Ongoing studies, combining data from multiple genomic methods, are helping to elucidate the genetic basis of Brugada Syndrome and other complex cardiac disorders with the aim of improving patient care in the future.
Register for the webinar to hear Professor Connie Bezzina present data from her laboratory and ongoing collaborative studies with the Brugada Syndrome Genetics Consortium.
The latest NovaSeq advancements have arrived—delivering unprecedented scalability and flexibility for next-generation sequencing (NGS). Discover how the S4 flow cell allows you to use the NovaSeq 6000 System to take your research to the next level.
Join Gary Schroth, Illumina Distinguished Scientist, to learn about these latest advancements with the NovaSeq 6000 System. See how the S4 can provide you the highest throughput of any sequencer. Finally, with the new NovaSeq Xp workflow, you can expand your research, giving you more flexibility than ever before.
See what happens when a leading library prep is optimized to run on next-generation sequencing (NGS) systems from Illumina. Join Mitu Chaudhary and Claire White as they present data to demonstrate the robust performance of AmpliSeq for Illumina from a wide variety of sample types.
Explore our smallest and most cost-effective sequencer ever. Join Bellal Moghis and Gary Schroth as they introduce our newest system—iSeq 100. They’ll walk through installation and also review applications and methods. Find out how you can make the most of your new lab partner.
Genomics is facilitating a deeper understanding of cancer biology and through clinical research, new biomarkers are emerging that pave the way for next-generation therapeutics to help fight cancer in a more personalized way.
In this webinar, Sandip Patel, MD will provide a review of biomarker research and discoveries in the field of Immunotherapy and Garret Hampton, PhD will discuss Illumina’s vision for Oncology and share how genomics will enable broader availability of comprehensive tumor sequencing to explore complex biomarkers and assess tumor mutational burden.
Understanding the microbial ecosystem dynamics of our planet is central to our role as custodians of the planet. The Earth Microbiome Project aimed to characterize the microbial diversity of the diverse ecosystems across our world, which we have used to model the ecosystem dynamics of these environments. Integrating these models with agricultural policy provides a framework on which to determine how climate change and shifting policy will influence the microbial metabolic dynamics, which will affect our ability to modulate system scale outcomes. In concert with this global perspective we are also characterizing the human microbiome, which has become a key part of patient care, provide new avenues to diagnose and treat human disease. The immune system controls our interaction with the microbial world, and yet the microbial communities in our bodies are central to modulating the immune response. Changes in the human microbiome have substantial influence on atopy, neurological disorders, metabolic disorders, and a range of complex conditions and disease states. We will discuss evidence of these mechanisms of interaction and how we have started to disturb the delicate balance of the immune-microbe equilibrium, impacting the development and function of our immune systems. Central to this disturbance is the distance we have placed between our children and the microbial world, which has been demonstrated to have a substantial influence on their physiological, immunological, neurological and even endocrinological development. Applying new strategies to identify how the microbial ecosystem correlates with diseases states and treatment efficacy through Microbiome-Wide Association Studies (MWAS) is altering the trajectory of precision medicine, and providing a new framework for facilitating patient care.
Jack Gilbert
Jack Gilbert is the Faculty Director of the Microbiome Center, a Professor in the Department of Surgery at the University of Chicago Medicine, Senior Scientist (Adjunct) at Marine Biological Laboratory, and Group Leader in Microbial Ecology at Argonne National Laboratory. Gilbert's research is focused on the ecology, evolution, and metabolic dynamics of microbial ecosystems from myriad environments including built environments, oceans, rivers, soils, air, plants, animals, and humans. His primary interest is in using omics technologies (metagenomics, metatranscriptomics, metabolomics) to capture longitudinal dynamics in microbial ecosystems and then model how these interactions relate the environmental variables, be those variables disease onset and immunology in humans or chemical transformations in plants and soils. Gilbert is developing unifying principles which govern how microbial communities assemble. He founded the Earth Microbiome Project, and co-founded the American Gut Project, and is the editor-in-chief of the journal mSystems.
Microbiome research is quickly becoming one of the most exciting fields in the life sciences, driven by the power of next-generation sequencing (NGS). One Codex is a leading platform for rapid, accurate microbiome and metagenomics analysis and is used by researchers across major academic, commercial, and clinical institutions. In this webinar, we will walk through a gut microbiome experiment including sample collection, sequencing, bioinformatics, and analysis.
On the bioinformatics side, we will show how you can easily analyze NGS datasets with the One Codex database of >80,000 whole microbial genomes. We will review several types of microbiome analyses from taxonomic classification to building predictive machine learning models. Finally, we will demonstrate how it can all be performed in a scalable, repeatable fashion, ensuring that your microbiome research is reproducible whether it involves 10 samples or 10,000.
This webinar discusses the use of shotgun metagenomics to identify children at risk of hospital-acquired infection.
Our speaker, David Haslam of Cincinnati Children's Hospital, details methods used to eradicate colonization with pathogenic organisms and hopefully prevent bloodstream infections. He also discusses how bacterial whole genome sequencing and shotgun metagenomics can be used to track and prevent transmission of hospital-acquired infections.
Dr. Haslam shares how this work fits within his lab's goal of identifying risk factors for invasive infection due to multidrug resistant bacteria. His team is applying next generation sequencing and metagenomic analysis to identify changes in the microbiome that correlate with risk for invasive infection and is currently developing this assay into a clinically actionable test.
See what new product developments are available in the Illumina sequencing portfolio. Join David Miller from Illumina Product Marketing, as he presents data in support of new software, robust sequencing kit performance, and longer reads on a variety of next-generation sequencing (NGS) systems from Illumina.
Illumina product development presents the next era of library prep. The new Nextera™ DNA Flex and Nextera™ DNA Flex for Enrichment library prep solutions deliver consistent insert sizes, uniform coverage, optimized performance, and highly reproducible data across all Illumina sequencing systems. This bead-based technology minimizes bias and opportunities for error, resulting in highly reproducible sequencing data.
The latest sequencing technologies enable unprecedented throughput and redefine limits for many labs. Join Shawn Levy, Faculty Investigator at the HudsonAlpha Institute for Biotechnology, as he presents data demonstrating how multiple Illumina sequencing systems can be utilized together in a lab setting to facilitate larger scale sequencing.
Data volumes are growing more rapidly than ever before. Join Menzies Chen, Illumina Product Manager, as he discusses the newest informatics features to support high throughput, high volume sequencing. With DRAGEN™ technology, bioinformatics workflows can now be run on specialized hardware to accelerate the speed of analysis.
Part 1: Transforming the Future of Genomics Together, with Gary Schroth, Distinguished Scientist, Illumina, Inc.
Learn about the most recent product developments from Illumina in library preparation, next-generation sequencing (NGS) systems, and informatics. Illumina Distinguished Scientist, Gary Schroth, presents a short overview on the newest in end to end next-generation sequencing (NGS) solutions as well as exciting new options for the future.
Part 2: HiSeq™, NovaSeq™, and iSeq™: Project Transitions to Leverage Larger Scale Sequencing, with Shawn Levy, Director of the HudsonAlpha Institute for Biotechnology
The latest sequencing technologies enable unprecedented throughput and redefine limits for many labs. Join Shawn Levy, Faculty Investigator at the HudsonAlpha Institute for Biotechnology, as he presents data demonstrating how multiple Illumina sequencing systems can be utilized together in a lab setting to facilitate larger scale sequencing.
Cancer arises due to an accumulation of genetic alterations, which can lead to the production of mutant proteins not expressed in normal cells, allowing recognition by the immune system. Kellie Smith, PhD, Assistant Professor of Oncology at Johns Hopkins University School of Medicine, presents her research on understanding the interplay of cancer neoantigens with the immune response at Illumina Exhibitor Spotlight Theater presentation at AACR 2019.
Advances in next-generation sequencing technology and computational data analysis have revolutionized efforts to identify tumor-specific mutant antigens. These altered, potentially immunogenic proteins may prove to be an important target for immunotherapies. In this Cell Press Webinar, Nicholas McGranahan (University College London) and Gerald Linette (University of Pennsylvania) will review progress made and future applications of this important area of cancer immunogenomics.
This webinar will discuss the benefits of virus-specific target capture combined with next-generation sequencing (NGS) to identify viral infections and conduct comprehensive genomic and transcriptomic interrogation.
The high diversity of inter-virus genome types and intra-virus genomic heterogeneity, together with the complexity of sample types, make NGS-based clinical virology difficult, arduous, and expensive. A single method that is able to use nucleic acids that are of low quantity and poor quality to examine both DNA and RNA viruses from a mixed cell population that may include human, bacteria, and viruses would be ideal.
To this end, our speaker, Darrell L. Dinwiddie of the University of New Mexico Health Sciences Center, will discuss a method his team has been evaluating that uses virus-specific target capture probe sets coupled with NGS.
Dr. Dinwiddie will discuss how this method has demonstrated significant improvement in respiratory viral identification and genome coverage compared to unenriched NGS. His team has shown the ability to effectively capture and sequence viruses that may differ from the probes by as much as 10 percent to 15 percent. These methods have worked for viral sequencing from purified viral stocks, in vitro cell culture, and clinical samples.
This webinar will also address the broader implications of this work, including surveillance, epidemiologic studies, and public health planning.
For example, in two hospital outbreak studies, Dr. Dinwiddie and colleagues have shown that target capture and NGS enabled sensitive discrimination of the relatedness of respiratory syncytial virus and human parainfluenza virus 3 isolates obtained during the outbreak and provided evidence for source of transmission.
In addition, through multi-year retrospective and prospective NGS studies of respiratory viral infections at multiple pediatric hospitals, Dr. Dinwiddie and his team have been able to examine seasonal respiratory virus genomic variation, evolution, and distribution for several respiratory viruses. This includes evaluating the match of vaccine to circulating influenza virus strains and the correlation between virus strains and clinical severity of infections. The recently developed Human Pan Viral sequencing methods by Illumina and Twist Biosciences will enable similar studies not only for respiratory viruses, but for all types of human viral pathogens across all sample types of interest.
Darrell L. Dinwiddie, PhD
Assistant Professor, Department of Pediatrics
Scholar, Clinical Translational Science Center
University of New Mexico Health Sciences Center
Watch this presentation to hear more about a novel approach that uses hybrid avatars and perturbation biology. The idea is to use complementary data to extract immunologically relevant information.
By combining the analysis of RNA sequencing and image data, Prof. Zlatko Trajanoski’s lab in Innsbruck has devised a powerful workflow that will enable precision immuno-oncology.